Dexcom (DXCM) Operating Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Operating Expenses data on file, last reported at $495.0 million in Q1 2026.

• Quarterly Operating Expenses rose 8.72% year-over-year to $495.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 5.3% YoY) and the FY2025 annual result came in at $1.9 billion, up 2.82% from the prior year.
• Operating Expenses grew to $495.0 million in Q1 2026 per DXCM's latest filing, from $469.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $495.0 million in Q1 2026 and bottomed at $346.7 million in Q3 2022.
• The 5-year median for Operating Expenses is $441.8 million (2024), against an average of $435.7 million.
• The widest annual swing landed in 2022, when Operating Expenses fell 11.89%; it then gained 20.51% in 2023.
• Tracing DXCM's Operating Expenses over 5 years: stood at $415.9 million in 2022, then increased by 5.72% to $439.7 million in 2023, then rose by 6.19% to $466.9 million in 2024, then grew by 0.6% to $469.7 million in 2025, then gained by 5.39% to $495.0 million in 2026.
• Per Business Quant, the three latest DXCM Operating Expenses figures stand at $495.0 million (Q1 2026), $469.7 million (Q4 2025), and $488.9 million (Q3 2025).

Peer Comparison